Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for ...

On Monday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a modest uptick, ending the day at $1.27 which represents no change from the prior close of of $1.27. The stock opened at $1.26 and touched a ...

Analysts are estimating that Lexicon Pharmaceuticals will report an earnings per share (EPS) of $-0.16. The announcement from Lexicon Pharmaceuticals is eagerly anticipated, with investors seeking ...

Lexicon Pharmaceuticals, Inc. - GlobeNewswire - Wed Nov 6, 7:00AM CST THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its ...

Lexicon Pharmaceuticals (NASDAQ:LXRX) is scheduled to announce Q3 earnings results on Tuesday, November 12th, after market ...

On Friday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $1.27 which represents a decrease of $-0.03 or -2.31% from the prior close of $1.3. The stock opened at $1.3 and ...

THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference.

Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' ...

An FDA advisory committee voted Thursday that it didn’t believe the benefits of Lexicon's (LXRX) diabetes drug sotagliflozin ...

Lexicon Pharmaceuticals (NASDAQ:LXRX) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent ...